VPIM
TCRX icon

Vanguard Personalized Indexing Management’s TScan Therapeutics TCRX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.6K Buy
21,359
+6,682
+46% +$7.14K ﹤0.01% 2119
2025
Q4 		$14.7K Sell
14,677
-6,315
-30% -$9.14K ﹤0.01% 1952
2025
Q3 		$38.2K Buy
20,992
+1,100
+6% +$1.95K ﹤0.01% 1932
2025
Q2 		$28.8K Buy
+19,892
New +$28.7K ﹤0.01% 1880

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Vanguard Personalized Indexing Management's TCRX Position: Q1 2026 in Review

Vanguard Personalized Indexing Management increased its TScan Therapeutics (TCRX) stake by 46% in Q1 2026, buying an estimated $7.14K and bringing the position to 21,359 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2119.

Vanguard Personalized Indexing Management first reported a position in TCRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $38.2K in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Vanguard Personalized Indexing Management held 21,359 shares of TScan Therapeutics worth $21.6K as of Q1 2026.
  • Vanguard Personalized Indexing Management bought 6,682 TScan Therapeutics shares in Q1 2026, an estimated $7.14K.
  • TScan Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #2119 holding.
  • Vanguard Personalized Indexing Management first reported a position in TScan Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Vanguard Personalized Indexing Management's TScan Therapeutics position peaked at $38.2K in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.